GLP-1 RAs in aging people with HIV

People with HIV are living longer than ever. Antiretroviral therapy (ART) now keeps the virus durably suppressed in most patients who access it, and life expectancy for someone diagnosed with HIV today in a high-income country approximates that of the general population. That success has produced a new clinical challenge: a rapidly aging population carrying a disproportionate burden of cardiometabolic disease^[1].

Obesity, type 2 diabetes, dyslipidaemia, hypertension, and metabolic-associated steatotic liver disease (MASLD) accumulate earlier and more severely in people with HIV (PWH) than in the general population. Drivers include chronic immune activation, the direct metabolic effects of some older ART agents, and the weight gain now documented with many integrase strand transfer inhibitors (INSTIs). A 2025 CROI review noted that large epidemiological studies had found an increased risk of diabetes and hypertension associated with INSTI class switches, independent of weight change^[2].

It is against this backdrop that semaglutide and other glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have entered HIV care. A July 2026 review in Current Opinion in HIV and AIDS by Lara Haidar and Joseph Delaney summarises the emerging evidence and its clinical implications^[1].

What the evidence shows on weight and cardiometabolic markers

The clearest finding across the HIV-specific literature is that GLP-1 RAs produce meaningful weight reduction in PWH. A 2024 review in Topics in Antiviral Medicine noted that weight reduction starting at 5% of body weight confers metabolic protection in this population, including improved hypertension and dysglycaemia, with more pronounced cardiovascular benefit at around 15% weight loss^[3].

A May 2026 analysis of 36 PWH on semaglutide published in AIDS found improvements in lipid profiles and inflammatory markers independent of changes in weight, liver fat, or insulin resistance. Specifically, triglycerides, diglycerides, and sphingomyelins fell; bile acids and phosphatidylcholines increased; and among participants with elevated inflammatory markers at baseline, more than half normalised GlycA levels. The authors described the lipid changes as the first such molecular characterisation in any patient population receiving semaglutide^[4].

A separate CNICS cohort analysis of 1,850 PWH across 10 clinical sites, also published in AIDS in May 2026, found that semaglutide correlated with reductions in liver fibrosis scores, particularly in those with moderate to advanced disease. Participants with advanced fibrosis saw a mean FIB-4 reduction of 0.64 (p less than 0.001) over a median treatment period of 218 days^[5].

The epigenetic aging signal

One of the more striking findings from 2026 concerns biological aging. A 32-week randomised controlled trial comparing semaglutide (n=45) to placebo (n=39) in adults with HIV-associated lipohypertrophy used DNA methylation profiling to measure epigenetic age. Published in Nature Communications in May 2026, the exploratory analysis found that semaglutide was associated with reductions across multiple epigenetic clocks: PhenoAge improved by approximately 4.9 years annually, GrimAge V2 by 2.3 years, and DunedinPACE indicated roughly 9% slower biological aging relative to placebo^[6]. The authors flagged the post-hoc design and modest sample size, and noted that prospective trials are needed before GLP-1 RAs can be repositioned as anti-aging interventions.

Potential effects on behavioural outcomes

Beyond cardiometabolic outcomes, the Haidar and Delaney review highlights preliminary signals on behavioural endpoints: alcohol use and smoking. The mechanistic basis is plausible given GLP-1 receptor expression in reward circuitry, but the HIV-specific evidence remains sparse. An open-label trial of liraglutide in 40 PWH in South Africa, published in Clinical Infectious Diseases in 2026, observed significant improvements in depressive symptoms, sleep quality, and psychological quality of life alongside weight reduction^[7]. These are secondary endpoints in a single-arm study, and the authors caution that most benefits reversed after stopping treatment.

Safety considerations specific to people with HIV

The Haidar and Delaney review identifies two safety areas that warrant particular attention in older PWH: lean mass loss and bone health. Both concerns apply to the general GLP-1 RA literature, but they may carry added weight in a population where sarcopenia and low bone density are already prevalent. The current HIV-specific data are limited, and the review characterises them as generally reassuring with functional outcomes largely preserved^[1].

Durability is another open question. A 2026 Clinical Infectious Diseases study followed 49 PWH (median age 52, median BMI 35) who stopped low-dose semaglutide after 24 weeks. During treatment, participants lost a mean of 7.8 kg. After stopping, they regained a mean of 2.9 kg over the following 24 weeks, along with increases in waist circumference and fasting glucose. The pattern is consistent with the discontinuation evidence in the general population^[8].

Research gaps and what is not yet known

Most HIV-specific GLP-1 RA trials to date have used lower semaglutide doses than those now standard in obesity practice (2.4 mg weekly). Evidence in older PWH specifically remains sparse despite this population carrying the highest cardiometabolic burden^[1]. Head-to-head comparisons with other weight-management strategies are absent. The interaction between GLP-1 RAs and specific ART regimens has not been systematically characterised. And cardiovascular outcomes data of the kind available from SELECT for semaglutide in the general population do not yet exist for PWH.

This article is for information only and does not constitute medical advice. People with HIV considering weight management or cardiometabolic treatment should speak with a healthcare provider familiar with their ART regimen and overall health.